OncoSec Medical (DE:ONMA)
FRANKFURT:ONMA
Holding DE:ONMA?
Track your performance easily

OncoSec Medical (ONMA) Stock Price & Analysis

1 Followers

ONMA Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

2.12%97.88%
Insiders
Mutual Funds
2.12% Other Institutional Investors
97.88% Public Companies and
Individual Investors

ONMA FAQ

What was OncoSec Medical’s price range in the past 12 months?
OncoSec Medical lowest stock price was €0.11 and its highest was €0.14 in the past 12 months.
    What is OncoSec Medical’s market cap?
    Currently, no data Available
    When is OncoSec Medical’s upcoming earnings report date?
    OncoSec Medical’s upcoming earnings report date is Mar 12, 2025 which is in 132 days.
      How were OncoSec Medical’s earnings last quarter?
      Currently, no data Available
      Is OncoSec Medical overvalued?
      According to Wall Street analysts OncoSec Medical’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does OncoSec Medical pay dividends?
        OncoSec Medical does not currently pay dividends.
        What is OncoSec Medical’s EPS estimate?
        OncoSec Medical’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does OncoSec Medical have?
        OncoSec Medical has 5,962,652 shares outstanding.
          What happened to OncoSec Medical’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of OncoSec Medical?
          Currently, no hedge funds are holding shares in DE:ONMA
          ---

          OncoSec Medical Stock Smart Score

          10
          Unlock Smart Score
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Company Description

          OncoSec Medical

          OncoSec Medical, Inc. is a biotechnology company, which engages in designing, developing, and commercializing therapies for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered inPennington, NJ.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Inovio Pharmaceuticals
          Oncternal Therapeutics
          Cellectar Biosciences
          Immutep
          OncoSec Medical
          Popular Stocks
          ---
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis